San Diego, CA -- (SBWire) -- 11/16/2022 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at BioLineRx Ltd.
Investors who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioLineRx Ltd. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Israel based BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd.
BioLineRx Ltd. reported that its Net Loss declined from $30.02 million in 2020 to $27.05 million in 2021.
Shares of BioLineRx Ltd. (NASDAQ: BLRX) declined from $3.15 per share on October 15, 2021, to as low as $0.84 per share on September 26, 2022.
Those who purchased shares of BioLineRx Ltd. (NASDAQ: BLRX) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
NASDAQ:BLRX Shareholder Alert: Investigation over Potential Wrongdoing at BioLineRx Ltd.
An investigation on behalf of investors in BioLineRx Ltd. (NASDAQ:BLRX) shares over potential wrongdoing at BioLineRx Ltd. was announced.